



UNIVERSITI PUTRA MALAYSIA

***COMPARATIVE ANALYSIS OF PATHOGENICITY PROFILES AND
ANTITUMOUR EFFECTS OF WILD AND MUTANT STRAINS OF
SALMONELLA ENTERICA SEROVAR AGONA***

GWEE CHIN PIAW

FPSK(M) 2015 82



**COMPARATIVE ANALYSIS OF PATHOGENICITY PROFILES AND
ANTITUMOUR EFFECTS OF WILD AND MUTANT STRAINS OF
SALMONELLA ENTERICA SEROVAR AGONA**

By

GWEE CHIN PIAW

**Thesis Submitted to the School of Graduate Studies, Universiti Putra
Malaysia, in Fulfilment of the Requirements for the Degree of Master of
Science**

October 2015

COPYRIGHT

All material contained within the thesis, including without limitation text, logos, icons, photographs and all other artwork, is copyright material of Universiti Putra Malaysia unless otherwise stated. Use may be made of any material contained within the thesis for non-commercial purposes from the copyright holder. Commercial use of material may only be made with the express, prior, written permission of Universiti Putra Malaysia.

Copyright © Universiti Putra Malaysia



Abstract of thesis presented to the Senate of University Putra Malaysia in
fulfilment of the requirement for the degree of Master of Science

**COMPARATIVE ANALYSIS OF PATHOGENICITY PROFILES AND
ANTITUMOUR EFFECT OF WILD AND MUTANT STRAINS OF
SALMONELLA ENTERICA SEROVAR AGONA**

By

GWEE CHIN PIAW

October 2015

Chair: Cheah Yoke Kqueen, PhD
Faculty: Medicine and Health Sciences

The fight against cancer has been a never ending battle. Cancer remains a major threat to human life. Limitations of conventional therapies included lack of selectivity, poor penetration and highly toxic to the host. One of the innovative approaches which have gained the interest of scientists from past few decades is the use of live, genetically modified bacteria as tumour therapy agent. Engineered bacteria possess unique features to overcome the limitations of conventional therapies. Low virulence and highly tolerability of *Salmonella* spp. in animals and humans make it as a most studied pathogen in regards to antitumour therapy. Genetically modified *S. Typhimurium* has been constructed as direct tumouricidal agent or as drug delivery vector in many researches. Main objective of this study is to construct genetically modified *S. Agona* as antitumour agent. A powerful genetic manipulation tool is needed in order to meet the requirements as tumouricidal agent in experimental and clinical research. Group II intron mutagenesis technology was exploited in current study to inactivate the metabolic genes in *S. Agona*. Group II intron technology has been shown to be able to insert at desired DNA at high frequency and specificity. In this study, *LeuB* and *ArgD* metabolic genes in *S. Agona* were successfully knockout at frequency of 15% and 3% respectively. Non-reverting and high stability of intron insertion was proven with a stability passage assay of 30 days culture. The constructed knockout *S. Agona* has become auxotrophic for leucine and arginine. Inactivation of *LeuB* and *ArgD* genes leads to a significant growth defect in M9 minimal media. *Salmonella* is a natural pathogen of mice, thus, mouse model was used to evaluate the potential pathogenicity and antitumour activity of engineered *S. Agona* in present work. Quadruple knockout BDLA exhibited highest safety among all of the strains in all tested parameters including bacterial colony forming units, immunity profile and histopathology studies. Tumour growth inhibition study was divided into two groups, which are small tumour model with size approximately 250 mm³ and large tumour model with size approximately 450 mm³ in comparison with each other.

Results have shown that all of the stains are able to delay the growth of the small and large solid tumour as compare to the negative control, with better efficacy shown by auxotrophic knockout strain LA and BDLA. Interestingly, tumour growth inhibition noticed on small tumour is not as effective as seen on large tumour, might be due to the better hypoxia or nutrient conditions available in microenvironment of big tumour. Furthermore, findings from this study showed that the treated groups with repeated treatment did not show any significant improvement in tumour growth delay, in both big and small solid tumour models. Overall, the virulence of BDLA knockout strain was reduced and antitumour effect was successfully enhanced. The results obtained from current work suggest a great potential of auxotrophic quadruple knockout *S. Agona* as antitumour agent.

Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia Sebagai memenuhi keperluan untuk Ijazah Master Sains

**PERBANDINGAN ANALISIS DALAM PROFIL KEPATOGENAN DAN
KESAN ANTITUMOUR ANTARA JENIS LIAR DAN STRAIN MUTAN
SALMONELLA ENTERICA SEROVAR AGONA**

Oleh

GWEE CHIN PIAW

Oktober 2015

Pengerusi: Cheah Yoke Kqueen, PhD
Fakulti: Perubatan dan Sains Kesihatan

Perlawanan menentang kanser telah menjadi pertempuran yang tidak berkesudahan. Kanser kekal menjadi ancaman utama kepada kehidupan manusia. Had-had terapi konvensional termasuk kekurangan selektiviti, penembusan yang lemah dan sangat toksik kepada tuan rumah. Salah satu cara inovatif yang mendapat minat daripada saintis-saintis dari beberapa dekad yang lepas ialah penggunaan bakteria yang hidup dan diubahsuai secara genetik sebagai agen terapi tumor. Bakteria yang telah diubahsuai mempunyai ciri-ciri unik untuk mengatasi batasan yang didapati dalam terapi konvensional. Tahap virulensi yang rendah dan toleransi yang tinggi pada haiwan dan manusia telah membolehkan *Salmonella* spp. Di antara patogen yang paling banyak dikaji dalam bidang terapi antitumor. *S. Typhimurium* yang diubahsuai secara genetik telah dihasilkan sebagai agen “tumouricidal” secara langsung atau sebagai vektor penyampai ubat dalam banyak kajian. Objektif utama kajian ini adalah untuk menghasilkan *S. Agona* pengubahsuaian genetik untuk dijadikan agen antitumor. Alat manipulasi genetik yang berkuasa diperlukan supaya dapat memenuhi syarat-syarat sebagai agen “tumouricidal” dalam kajian eksperimental dan percubaan klinikal. Dalam kajian ini, teknologi mutagenesis Intron Kumpulan II telah dieksploitasi untuk menyahaktifkan gen metabolik dalam *S. Agona*. Kaedah Teknologi Intron Kumpulan II telah terbukti berjaya dapat memasukkan DNA yang diingini pada frekuensi and spesifikasi yang tinggi. Dalam kajian ini, gen metabolik *LeuB* dan *ArgD* dalam *S. Agona* telah berjaya disingkir keluar secara genetik pada frekuensi 15% dan 3% masing-masing. Kemasukkan intron dengan kestabilan tinggi dan tanpa pengembalian ke asal telah terbukti dengan ujian kestabilan (stability passage assay) pada kultura sehingga 30 puluh hari. *S. Agona* yang diubah suai secara genetik telah menjadi auksotrofik kepada leusina dan arginina. Keupayaan pertumbuhan ganda dua mutan $\Delta LeuB \Delta ArgD$ (LA) dan ganda empat mutan $\Delta SopB \Delta SopD \Delta LeuB \Delta ArgD$ (BDLA) dalam M9 media minumum telah berjaya dilumpuhkan. Oleh kerana *Salmonella* merupakan patogen semula jadi yang didapati dalam tikus, maka model tetikus telah digunakan untuk menilai tahap kepatogenan dan potensi antitumor aktiviti

kejuruteraan *S. Agona* dalam kajian ini. Mutant ganda empat BDLA dapat menunjukkan tahap keselamatan yang tertinggi di antara semua jenis *Salmonella* dalam semua parameter yang diuji, termasuk unit pembentukan koloni bakteria, profil imuniti and juga kajian histopatologi. Kajian perencatan pertumbuhan tumor telah dibahagikan kepada dua kumpulan, iaitu tumor besar (~450 mm³) dan tumor kecil (~250 mm³). Keputusan dalam kajian ini telah menunjukkan semua jenis *Salmonella* dapat melambatkan pertumbuhan tumor kecil and besar berbanding dengan kumpulan kawalan negatif, dengan keberkesanan yang lebih baik ditunjukkan oleh LA dan BDLA mutan auksotrof. Yang menariknya ialah pencegahan pertumbuhan tumor pada tumor kecil tidak begitu baik seperti yang dapati dalam tumor besar, kemungkinan ini disebabkan oleh keadaan hipoksia dan nutrien yang lebih baik didapati dalam tumor besar. Tambahan pula, keputusan menunjukkan bahawa kumpulan dengan ulangan rawatan tidak menunjukkan sebarang peningkatan yang ketara dalam pencegahan pertumbuhan tumor sama ada tumor kecil atau besar. Secara keseluruhan, virulensi BDLA mutan dapat dikurangkan dan kapasiti perencatan tumor tidak terjejas, sebaliknya ia menunjukkan peningkatan dalam efikasi terhadap tumor besar. Sebagai kesimpulan, keputusan kajian ini menunjukkan bahawa mutan *S. Agona* auksotrofik dengan ganda-empat berpotensi tinggi sebagai agen perencat tumor.

ACKNOWLEDGEMENTS

First and foremost, my acknowledgments of university personalities begin with my project supervisor, Assoc. Prof. Dr. Cheah Yoke Kqueen for his help and expertise during the process of creating my thesis. I wish to convey my deepest gratitude for his patient, stimulating discussion, insightful suggestions, critical review and continuous guidance throughout my academic program. I would also like to express my appreciation to my co-supervisor, Assoc. Prof. Dr. Sabrina Sukardi for her guidance and valuable advices in making this project meaningful. I am also indebted to Dr. Khoo Chai Hoon, postdoctoral research fellow in molecular biology lab, for being my mentor throughout the duration of my master study. Her willingness in knowledge sharing, advices and encouragements has contributed tremendously to my research. The generous sacrifice of her time and innumerable suggestions that helped me improve this piece of work will never be forgotten.

Special thanks go to Dr. Yeap Swee Keong from Institute of Bioscience, UPM, for his valuable suggestions on the experimental design of my research, as well as his expertise advice on flow cytometry analysis, which contribute to part of my study. Not to forget as well, I would particularly like to thank Assoc. Prof. Dr. Tan Geok Chin, consultant pathologist at HUKM, for his enthusiastic knowledge sharing, teaching and professional guidance on histopathology section, this piece of work would never be completed without his contribution.

I would like to express my sincerest appreciation to my labmate Chu Wern Cui and Chu Pek Lim, by giving helping hand on animal works till the late night when I was shorthanded. Thanks Wern Cui for the guidance and advice in statistical analysis as well. Their unconditional supports and helps will never be forgotten. A special note of thanks also goes to my other labmates and friends from UPM, Elaine Chin JinFeng, See Tian Hong, Irene Chen Bao Jing, Ooi Kah Kooi, Chew Shu Yih, Daran Goh Zheng Jie and Sim Juin Horng for sharing laughter and tears for the past two years. When I met any difficulties or doubts on my research project, they are always there to share their opinions and suggestions. I am also grateful to Mr. Ramli at animal house, UPM, in helping me to obtain the source of mice for research study. Thanks also to the lab assistant, Kak Martini for helping me in lab throughout my study.

A thousand of thanks go to my dearest grandparents, parents and my siblings for their financial and mentally supports throughout my endeavours. I am where i am just because of your undying love and understanding. The list would not be completed without giving credit to Ms. Ng Pei Vun, my beloved partner. Her understanding, personal support, and constant encouragement helped me to overcome moments of doubt and to enjoy life beyond science. Last but not least, for all those who involved, may God of love and peace be with you all.

The thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of the Supervisory Committee were as follows:

Cheah Yoke Kqueen, PhD

Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Sabrina Sukardi, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)

BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

Declaration by Members of Supervisory Committee

This is to confirm that:

- the research conducted and the writing of this thesis was under our supervision;
- supervision responsibilities as stated in the Universiti Putra Malaysia (Graduate Studies) Rules 2003 (Revision 2012-2013) are adhered to.

Signature: _____

Name of
Chairman of
Supervisory
Committee: _____

Signature: _____

Name of
Member of
Supervisory
Committee: _____

TABLE OF CONTENTS

ABSTRACT	Page
ABSTRAK	i
ACKNOWLEDGEMENT	iii
APPROVAL	v
DECLARATION	vi
LIST OF TABLES	viii
LIST OF FIGURES	xiii
LIST OF ABBREVIATIONS	xiv
CHAPTER	xvii
1 INTRODUCTION	1
2 LITERATURE REVIEW	3
2.1 Cancer overview	3
2.2 Colorectal cancer	3
2.3 Conventional therapies	3
2.4 Challenges of cancer treatment in solid tumour	4
2.5 Microbial-based cancer therapy	6
2.5.1 The ways bacteria address the issues in cancer treatment	7
2.5.2 Targeting solid tumour with anaerobic and facultative anaerobic bacteria	8
2.5.3 <i>Salmonella</i> as antitumour agent	9
2.5.4 Genetically modified <i>Salmonella</i> in anticancer clinical studies	10
2.5.5 <i>Salmonella</i> -based antitumour activities	10
2.6 <i>Salmonella</i>	11
2.6.1 Incidence and epidemiology	12
2.6.2 <i>Salmonella enterica</i> serovar Agona	13
2.6.3 Virulence and pathogenicity	13
2.7 <i>SopB</i> and <i>SopD</i> virulence genes	14
2.8 <i>LeuB</i> and <i>ArgD</i> metabolic genes	15
2.9 Genetic modification – Group II intron technology	17
2.10 Cancer mouse model	18
3 METHODOLOGY	19
3.1 Construction of genetically modified <i>Salmonella enterica</i> serovar Agona	19
3.1.1 Bacterial strains, growth and storage conditions	19
3.1.2 DNA extraction	19
3.1.3 DNA sequences alignment of <i>LeuB</i> and <i>ArgD</i> genes	19
3.1.4 Target site selection and primer ordering	20
3.1.5 Preparation of <i>Salmonella</i> electrocompetent cells	23

3.1.6	Generation of retargeted introns by PCR	23
3.1.7	Construction of retargeted targetron plasmid	24
3.1.8	Transformation into cloning strain by heat-shock method	24
3.1.9	Electrotransformation of <i>S. Agona</i>	25
3.1.10	Induction of chromosomal gene disruption	25
3.1.11	Confirmation and purification of intron inserted mutant by colony PCR	26
3.1.12	Curing of the tagetron donor plasmid from successful single knockout	26
3.1.13	Construction of multiple knockout strains	26
3.1.14	Curing plasmid from multiple knockout strains	27
3.1.15	Stability assessment of transformed knockout strains	27
3.2	<i>in vitro</i> growth assessment of knockout strains	27
3.3	<i>in vitro</i> anticancer effect of different <i>Salmonella</i> strains	28
3.3.1	Cancer cell lines and growth conditions	28
3.3.2	Cell proliferation assay	28
3.3.3	Measurement of bacterial invasion	28
3.4	<i>in vivo</i> toxicity profile of <i>Salmonella</i>	29
3.4.1	Survival test analysis	29
3.4.2	Evaluation of potential toxicity of bacterial infection	29
	3.4.2.1 Bacterial replication in murine organs	29
	3.4.2.2 Immunophenotyping of splenocytes	30
	3.4.2.3 Hematoxylin-eosin staining of tissue sections	30
	3.4.2.4 Full blood count analysis	30
3.5	Antitumour effect exert by <i>Salmonella</i> strains	31
3.5.1	<i>in vivo</i> tumour growth inhibition	31
3.5.2	Analysis of bacterial distribution in tumour-bearing mice	31
3.5.3	Immunophenotyping of splenocytes, hematoxylin-eosin of tissue sections and full blood count analysis	31
3.6	Statistical analysis	32
4	RESULTS	33
4.1	Construction of genetically modified <i>Salmonella</i>	33
4.2	The <i>in vitro</i> assessment of growth ability of knockout strains	36
4.3	The <i>in vitro</i> anticancer assay on CT-26 murine colon carcinoma cell line	37
4.3.1	Evaluation of anticancer effect using time-dependent cell response profiles (TCRPs) technology	37
4.3.2	Gentamicin protection assay/ invasion assay	38
4.4	Comparison of pathogenicity between wild-type and genetically modified <i>S. Agona</i> in mice model	39
4.4.1	Mice survivability following intraperitoneal	39

	administration	
4.4.2	Infection of tumour-free mice and recovery of bacteria from vital organs	41
4.4.3	Effects of bacterial infection on the immunological response of mice	45
4.4.4	Histological analysis of organs in tumour-free mice	50
4.5	Evaluation of potential toxicity of <i>S. Agona</i> in CT-26 tumour-bearing mice	56
4.5.1	Organs and tumour colonization by wild-type and attenuated <i>S. Agona</i>	56
4.5.2	Bacterial load in liver: Tumour ratio	58
4.5.3	Effects of bacterial administration on the immunological response of tumour-bearing mice	58
4.5.4	Histological analysis of organs in tumour-bearing mice	61
4.5.5	Comparison of bacterial load and immunological response between virulence study and tumour growth inhibition study	68
4.6	Tumour growth suppression study	75
4.6.1	Mean relative tumour volume following treatment of <i>Salmonella</i>	75
4.6.2	Ratio of treated over control tumour volume (T/C %) following treatment of <i>Salmonella</i>	77
4.6.3	Comparison of antitumour efficacy between single and multiple administration of treatment	78
4.6.4	Body Weight	80
5	DISCUSSION	81
6	SUMMARY, CONCLUSION AND RECOMMENDATIONS FOR FUTURE RESEARCH	89
6.1	Summary and conclusion	89
6.2	Recommendations for future research	90
	REFERENCES	91
	APENDICES	111
	BIODATA OF STUDENT	117

LIST OF TABLES

Table		Page
2.1	<i>Salmonella</i> species, subspecies, serovars and their habitats	12
3.1	Primers and optimized PCR programme used to target metabolic genes in <i>S. Agona</i>	21
3.2	Primers required for targeted disruption of metabolic genes in <i>S. Agona</i>	22
4.1	Mice mortality after administration of different <i>S. Agona</i> strains	40
4.2	Degree of inflammation in murine organs three days after infection with wild-type and mutant strains of <i>S. Agona</i> .	50
4.3	Degree of inflammation in murine organs ten days after infection with wild-type and mutant strains of <i>S. Agona</i> .	50
4.4	Tumour-specific distribution of wild-type and genetically modified <i>S. Agona</i>	58
4.5	Degree of inflammation in organs of tumour-bearing mice three days after infection with wild-type and mutant strains of <i>S. Agona</i>	61
4.6	Degree of inflammation in organs of tumour-bearing mice ten days after infection with wild-type and mutant strains of <i>S. Agona</i>	61

LIST OF FIGURES

Figure		Page
2.1	Microbial leucine biosynthetic pathway	15
2.2	Microbial arginine biosynthetic pathway	16
4.1	Agarose gel picture of SOE PCR amplification showing successful retargeted intron in <i>S. Agona</i>	33
4.2	Agarose gel picture of colony PCR Screening of <i>LeuB</i> gene knockout <i>S. Agona</i> using gene-specific primer	34
4.3	Agarose gel picture of colony PCR Screening of <i>ArgD</i> gene knockout <i>S. Agona</i> using gene-specific primer	34
4.4	Agarose gel picture of PCR products for the confirmation of pure <i>S. Agona</i> clone after purification and genetically assessment	35
4.5	Growth kinetics of wild-type <i>S. Agona</i> , double knockout $\Delta SopB\Delta SopD$, double knockout $\Delta LeuB\Delta ArgD$, and quadruple knockout $\Delta SopB\Delta SopD\Delta LeuB\Delta ArgD$ in M9 minimal media with different conditions	36
4.6	Dynamic monitoring of CT-26 cancer cells responses to <i>Salmonella</i> infection	37
4.7	<i>in vitro</i> invasion activity of wild-type and genetically engineered <i>Salmonella</i> on CT-26 cell line	38
4.8	Colony forming unit assessment of wild-type (W), double knockout $\Delta SopB\Delta SopD$ (BD), double knockout $\Delta LeuB\Delta ArgD$ (LA), and quadruple knockout $\Delta SopB\Delta SopD\Delta LeuB\Delta ArgD$ (BDLA) in tumour-free mice	42
4.9	Colonization of spleen, liver, lung, kidney and intestine in tumour-free mice by wild-type and mutants <i>S. Agona</i> after intraperitoneal administration	44
4.10	Total white blood cell concentrations in tumour-free mice post administration	45
4.11	Analysis of blood neutrophil level in tumour-free mice	46
4.12	Analysis of blood lymphocyte level in tumour-free mice	47
4.13	Subpopulation analysis of CD4 ⁺ T cells in the spleen of mice	48
4.14	Subpopulation analysis of CD8 ⁺ T cells in the spleen of mice	49
4.15	Representative histopathology analyses of spleen sections excised from the PBS control, wild-type treated and BDLA treated tumour-free mouse after 10 days of intraperitoneal injection (H&E, 100 X)	51
4.16	Representative histopathology analyses of liver sections excised from the PBS control, wild-type treated and BDLA treated tumour-free mouse after 10 days of intraperitoneal injection (H&E, 40 X)	52
4.17	Representative histopathology analyses of lung sections excised from the PBS control, wild-type treated and BDLA treated tumour-free mouse after 10 days of intraperitoneal injection (H&E, 40 X)	53

4.18	Representative histopathology analyses of kidney sections excised from the PBS control,wild-type treated and BDLA treated tumour-free mouse after 10 days of intraperitoneal injection (H&E, 100 X).	54
4.19	Representative histopathology analyses of intestine sections excised from the PBS control,wild-type treated and BDLA treated tumour-free mouse after 10 days of intraperitoneal injection (H&E, 100 X)	55
4.20	Colonization of spleen, liver, lung, kidney and intestine in CT-26 tumour-bearing mice by wild type and mutants <i>S. Agona</i> A32 after intraperitoneal administration	57
4.21	Analysis of blood neutrophil level in CT-26 tumour-bearing mice	58
4.22	Analysis of blood lymphocyte level in CT-26 tumour-bearing mice	60
4.23	Subpopulation analyses of CD4 ⁺ and CD8 ⁺ T cells in the spleen of tumour-bearing mice	60
4.24	Representative histopathology analyses of spleen sections excised from the PBS control,wild-type treated and BDLA treated tumour-bearing mouse after 10 days of intraperitoneal injection (H&E, 100 X)	62
4.25	Representative histopathology analyses of liver sections excised from the PBS control,wild-type treated and BDLA treated tumour-bearing mouse after 10 days of intraperitoneal injection. (H&E, 40 X)	63
4.26	Representative histopathology analyses of lung sections excised from the PBS control,wild-type treated and BDLA treated tumour-bearing mouse after 10 days of intraperitoneal injection (H&E, 40 X)	64
4.27	Representative histopathology analyses of kidney sections excised from the PBS control,wild-type treated and BDLA treated tumour-bearing mouse after 10 days of intraperitoneal injection (H&E, 100 X)	65
4.28	Representative histopathology analyses of intestine sections excised from the PBS control,wild-type treated and BDLA treated tumour-bearing mouse after 10 days of intraperitoneal injection (H&E, 100 X)	66
4.29	Representative histopathology analyses of tumour sections excised from the PBS control,wild-type treated and BDLA treated tumour-bearing mouse after 10 days of intraperitoneal injection (H&E, 40 X)	67
4.30	Comparison analysis of bacterial load in the spleen between tumour-free mice and CT-26 tumour-bearing mice	68
4.31	Comparison analysis of bacterial load in the liver between tumour-free mice and CT-26 tumour-bearing mice	69
4.32	Comparison analysis of bacterial load in the lung between tumour-free mice and CT-26 tumour-bearing mice	70
4.33	Comparison analysis of bacterial load in the kidney between tumour-free mice and CT-26 tumour-bearing mice	71

4.34	Comparison analysis of bacterial load in the intestine between tumour-free mice and CT-26 tumour-bearing mice	72
4.35	Comparison analysis of blood neutrophil percentage between tumour-free mice and CT-26 tumour-bearing mice	73
4.36	Comparison analysis of blood lymphocyte percentage between tumour-free mice and CT-26 tumour-bearing mice	74
4.37	Mean relative tumour volume in small and big tumour model with single and multiple administration of the treatments	76
4.38	The percentage change in tumour size of the treated related to the control group (T/C) in big and small tumour model with single and multiple administration of treatments	77
4.39	Comparison of mean relative tumour volume between single and multiple injections in big tumour model after administration of W, BD, LA and BDLA <i>S. Agona</i>	78
4.40	Comparison of mean relative tumour volume between single and multiple injection in small tumour model after administration of W, BD, LA and BDLA <i>S. Agona</i>	79
4.41	Body weight of CT-26 tumour-bearing mice post treatment of wild-type and engineered strains of <i>S. Agona</i>	80

LIST OF ABBREVIATIONS/ SYMBOLS, UNITS AND TERMS

ATCC	American Type Culture Collection
bp	Base pair
CFU	Colony forming unit
DNA	Deoxyribonucleic acid
dNTP	Deoxyribonucleotide triphosphate
h	Hour
IPTG	Isopropyl-Beta-D-Thiogalactopyranoside
kb	Kilobase pair
LB	Luria Bertani
mL	Mililiter
mm	Millimeter
min	Minute
MOI	Multiplicity of infection
OD	Optical density
PCR	Polymerase chain reaction
RNA	Ribonucleic acid
RPM	Revolutions per minute
s	Second
X-gal	5-Bromo-4-Chloro-3-Indolyl-Beta-D-Galacto-Pyranoside
XLD	Xylose lysine deoxycholate
Δ	Mutant
°C	Degree celcius
%	Percentage
μg	Microgram
μM	Micromolar
μl	Microliter

CHAPTER 1

INTRODUCTION

Cancer is one of the leading causes of morbidity and mortality worldwide. Most of the patients are found at the late stage of disease and more than half of the patients diagnosed with cancer eventually die from this disease (Jemal et al., 2011). Conventional anticancer therapies, such as chemotherapy, radiotherapy and surgery often encounter significant side effects and fail to achieve complete tumour remission. These standard therapies do not target tumour tissue specifically and do not successfully penetrate deep into tumour tissue (Jain, 1998; Tannock et al., 2002), which ultimately leads to loss of local control and tumour recurrence (Davis and Tannock, 2002). A new paradigm for cancer drug development is therefore urgently needed.

The use of bacteria in the tumour regression in certain forms of cancer has been recognized for more than a century. Certain live, attenuated non-pathogenic bacteria such as *Salmonella*, *Bifidobacterium*, *Clostridium*, and *Listeria* possess unique features to overcome all these limitations (Pawelek et al., 2003; Morrissey et al., 2010; Taniguchi et al., 2010). Tumour microenvironment is often characterized by mass and abnormal tissue architecture, leads to disorganized and variable blood flow, which eventually creates heterogeneous microenvironment, including gradients chemical concentration and also hypoxia regions, make it particularly resistant to systemic treatment (Klemm and Joyce, 2014; Cairns et al., 2006). Bacteria are able to survive and proliferate within tumour microenvironment with very little oxygen whereby most of the times radiotherapy and chemotherapy are unsuccessful. Bacteria mostly are motile, able to penetrate into tumour tissue (St Jean et al., 2008; Lee, 2012). Although several bacteria species has been reported as anticancer agent, however, most of the current approaches are focused on *Salmonella* strains.

Salmonella characteristics such as motility, propagation control with antibiotics, genetic stability, environmental sensing, native cytotoxicity, low cost of production and safety make it a suitable choice as anticancer agent (Chorobik et al., 2013). *Salmonella* is able to produce certain virulence factors that lead to cytotoxicity and induce innate immunity to target tumour which helps in further tumour regression (Lee et al., 2008; Lee, 2012; Kaimala et al., 2014). Besides that, unlike other therapeutic agents, *Salmonella* can be delivered in low dose follow by proliferation to an effective dose within the target tumour (Forbes et al., 2003). An advantage of *Salmonella* to obligate anaerobes, the growth of facultative bacteria is not restricted to hypoxic environment. Therefore, this pathogen are able to colonize large and small tumour, and even accumulate within metastases after systemic administration (Leschner and Weiss, 2010; Yam et al., 2010).

The virulence of *Salmonella* is attenuated in some genetic modification. It was reported that *Salmonella* auxotroph with the deletion of *msbB* and *purI* gene would preferentially replicate within tumours when inject into tumor-bearing mice, showing tumour to normal tissue ratio exceeding 1000:1. The accumulation of *Salmonella* in tumour is accompanied by delaying the growth of tumour (Pawelek et al., 1997). In order to enhance their oncolytic effects, *Salmonella* strains were engineered as delivery vector to express effector genes such as those encoding angiogenic inhibitors (Lee et al., 2005) or prodrug converting enzymes (Pawelek et al., 1997; King et al., 2002).

Altogether, bacterial anticancer therapy has made great steps in past decades. In spite of the advantages and potential for live bacteria as antitumour agent, it is clear that in many cases fundamental work and issues are need to be addressed in order to limit the side-effects and to improve the efficacy of the system. Apparently, a powerful genetic engineering tool is desirable in order to reduce toxicity on host and meanwhile develop or enhance therapeutic activity. This study describes the use of group II intron technology for genetic manipulation of metabolic genes in *Salmonella* Agona. Mouse as natural host for *Salmonella* serovars was used as ideal experimental model for *in vivo* antitumour study and toxicity assay in present work. The constructed genetically modified *S. Agona* leucine and arginine auxotroph was expected to exhibit lower virulence in terms of bacterial colony forming unit, immunity profile and also histopathological analysis as compared to wild-type *S. Agona*. In addition, this particular knockout auxotrophic strain will be attracted by tumour microenvironment which is high in nutrient and subsequently exhibit higher antitumour efficacy. By taking initiative of constructing genetically modified *Salmonella* Agona and *in vivo* assay, it will greatly improve our understanding regarding the principle of group II intron genetic modification tool, the contribution of metabolic genes on antitumour activity and toxicity, and also novel use of *S. Agona* as antitumour agent.

Objectives of the study

The study was undertaken with the following objectives:

1. To construct genetically modified *S. Agona* by further inactivation of *LeuB* and *ArgD* metabolic genes
2. To investigate cytotoxic effects of engineered *S. Agona* *in vivo*
3. To evaluate the antitumour activity of engineered *S. Agona* *in vitro* and *in vivo*

REFERENCES

- Akhtar, P. and Khan, S.A. (2012). Two independent replicons can support replication of the anthrax toxin-encoding plasmid pXO1 of *Bacillus anthracis*. *Plasmid*, 67(2), 111-117.
- Alonzo, F., Port, G.C., Cao, M. and Freitag, N. E. (2009). The posttranslocation chaperone PrsA2 contributes to multiple facets of *Listeria monocytogenes* pathogenesis. *Infection and Immunity*, 77(7), 2612-2623.
- Asanuma, K., Kobayashi, D., Furuya, D., Tsuji, N., Yagihashi, A. and Watanabe, N. (2002). A role for survivin in radioresistance of pancreatic cancer cells. *Cancer Science*, 93(9), 1057-1062.
- Barak, Y., Schreiber, F., Thorne, S. H., Contag, C. H. and Matin, A. (2010). Role of nitric oxide in *Salmonella typhimurium*-mediated cancer cell killing. *BMC Cancer*, 10(1), 146.
- Barrow, P., Huggins, M. and Lovell, M. (1994). Host specificity of *Salmonella* infection in chickens and mice is expressed in vivo primarily at the level of the reticuloendothelial system. *Infection and Immunity*, 62(10), 4602-4610.
- Bauer, C.D. and Berg, C.P. (1943). The Amino Acids Required for Growth in Mice and the Availability of their Optical Isomers Three Figures. *The Journal of Nutrition*, 26(1), 51-63.
- Baumann, M., Krause, M. and Hill, R. (2008). Exploring the role of cancer stem cells in radioresistance. *Nature Reviews Cancer*, 8(7), 545-554.
- Baumler, A.J., Tsolis, R.M., Ficht, T.A. and Adams, L.G. (1998). Evolution of Host Adaptation in *Salmonella enterica*. *Infection and Immunity*, 66(10), 4579-4587.
- Beli, E., Duraku, E. and Telo, A. (2001). *Salmonella* serotypes isolated from chicken meat in Albania. *International journal of food microbiology*, 71(2), 263-266.
- Berche, P., Gaillard, J.L., Geoffroy, C. and Alouf, J.E. (1987). T cell recognition of listeriolysin O is induced during infection with *Listeria monocytogenes*. *The Journal of Immunology*, 139(11), 3813-3821.
- Binotto, J., MacLachlan, P.R. and Sanderson, K.E. (1991). Electrotransformation in *Salmonella Typhimurium*. *Canadian Journal of Microbiology* 37:474-478.
- Brenner, F., Villar, R., Angulo, F., Tauxe, R. and Swaminathan, B. (2000). *Salmonella* nomenclature. *Journal of Clinical Microbiology*, 38(7), 2465-2467.

- Brown, J.M. and Wilson, W.R. (2004). Exploiting tumour hypoxia in cancer treatment. *Nature Reviews Cancer*, 4(6), 437-447.
- Brumell, J.H., Kujat-Choy, S., Brown, N.F., Vallance, B.A., Knodler, L.A. and Finlay, B.B. (2003). SopD2 is a novel type III secreted effector of *Salmonella typhimurium* that targets late endocytic compartments upon delivery into host cells. *Traffic*, 4(1), 36-48.
- Bumann, D. (2009). System-level analysis of *Salmonella* metabolism during infection. *Current Opinion In Microbiology*, 12(5), 559-567.
- Buxton, A. (1957). Salmonellosis in Animals. A Review. *Salmonellosis in Animals. A Review*, 209.
- Cairns, R., Papandreou, I. and Denko, N. (2006). Overcoming physiologic barriers to cancer treatment by molecularly targeting the tumor microenvironment. *Molecular Cancer Research*, 4(2), 61-70.
- Camilli, A., Tilney, L.G. and Portnoy, D.A. (1993). Dual roles of plcA in *Listeria monocytogenes* pathogenesis. *Molecular Microbiology*, 8(1), 143-157.
- Campbell, I., Polyak, K., & Haviv, I. (2009). Clonal mutations in the cancer-associated fibroblasts: the case against genetic coevolution. *Cancer research*, 69(17), 6765-6769.
- Candales, M.A., Duong, A., Hood, K.S., Li, T., Neufeld, R.A., Sun, R., McNeil, B.A., Wu, L., Jardine, A.M. and Zimmerly, S. (2011). Database for bacterial group II introns. *Nucleic Acids Research*, gkr1043.
- Carter, P. (1975). Spread of enteric fever bacilli from the intestinal lumen. *Microbiology*, 182-187.
- Carter, P.B., and Collins, F.M. (1974). The route of enteric infection in normal mice. *The Journal of Experimental Medicine*, 139(5), 1189-1203.
- Chan, D.S., Lau, R., Aune, D., Vieira, R., Greenwood, D.C., Kampman, E. and Norat, T. (2011). Red and processed meat and colorectal cancer incidence: meta-analysis of prospective studies. *PloS One*, 6(6), e20456.
- Chang, W.W., Lai, C.H., Chen, M.C., Liu, C.F., Kuan, Y.D., Lin, S.T. and Lee, C.H. (2013). *Salmonella* enhance chemosensitivity in tumor through connexin 43 upregulation. *International Journal of Cancer*, 133(8), 1926-1935.
- Chen, G., Wei, D.P., Jia, L.J., Tang, B., Shu, L., Zhang, K., Xu, Y., Gao, J., Huang, X.F. and Jiang, W.H. (2009). Oral delivery of tumor-targeting *Salmonella* exhibits promising therapeutic efficacy and low toxicity. *Cancer Science*, 100(12), 2437-2443.

- Chen, Y., Caruso, L., McClane, B., Fisher, D. and Gupta, P. (2007). Disruption of a toxin gene by introduction of a foreign gene into the chromosome of *Clostridium perfringens* using targetron-induced mutagenesis. *Plasmid*, 58(2), 182-189.
- Chen, Y., McClane, B.A., Fisher, D.J., Rood, J.I. and Gupta, P. (2005). Construction of an alpha toxin gene knockout mutant of *Clostridium perfringens* type A by use of a mobile group II intron. *Applied and Environmental Microbiology*, 71(11), 7542-7547.
- Cheon, D.J. and Orsulic, S. (2001). Mouse models of cancer. *Annual Review of Pathology: Mechanisms of Disease*, 6(6), 95-119.
- Chorobik, P., Czaplicki, D., Ossysek, K., & Bereta, J. (2013). Salmonella and cancer: from pathogens to therapeutics. *Acta Biochim Pol*, 60(3), 285-297.
- Coley, W.B. (1891). II. Contribution to the Knowledge of Sarcoma. *Annals of Surgery*, 14(3), 199.
- Coley, W.B. (1910). The treatment of inoperable sarcoma by bacterial toxins (the mixed toxins of the *Streptococcus erysipelas* and the *Bacillus prodigiosus*). *Proceedings of the Royal Society of Medicine*, 3(Surg Sect), 1.
- Connolly, J., Schnitt, S., Wang, H., Longtine, J., Dvorak, A., Dvorak, H., Kufe, D., Pollock, R. and Weichselbaum, R. (2003). Tumor Structure and Tumor Stroma Generation. *Holland-Frei Cancer Medicine*.
- Corvaglia, A.R., François, P., Hernandez, D., Perron, K., Linder, P. and Schrenzel, J. (2010). A type III-like restriction endonuclease functions as a major barrier to horizontal gene transfer in clinical *Staphylococcus aureus* strains. *Proceedings of the National Academy of Sciences*, 107(26), 11954-11958.
- Costa, G.L. and Weiner, M.P. (2006). Colony PCR. *Cold Spring Harbor Protocol* doi: 10.1101/pdb.prot4141.
- Criss, A.K. and Casanova, J.E. (2003). Coordinate regulation of *Salmonella enterica* serovar Typhimurium invasion of epithelial cells by the Arp2/3 complex and Rho GTPases. *Infection and Immunity*, 71(5), 2885-2891.
- Crull, K., Bumann, D. and Weiss, S. (2011). Influence of infection route and virulence factors on colonization of solid tumors by *Salmonella enterica* serovar Typhimurium. *FEMS Immunology & Medical Microbiology*, 62(1), 75-83.
- Crum-Cianflone, N.F. (2008). Salmonellosis and the gastrointestinal tract: more than just peanut butter. *Current Gastroenterology Reports*, 10(4), 424-431.

- Crump, J.A., Luby, S.P. and Mintz, E.D. (2004). The global burden of typhoid fever. *Bulletin of the World Health Organization*, 82(5), 346-353.
- Crump, J.A. and Mintz, E.D. (2010). Global trends in typhoid and paratyphoid fever. *Clinical Infectious Diseases*, 50(2), 241-246.
- Cunin, R., Glansdorff, N., Pierard, A. and Stalon, V. (1986). Biosynthesis and metabolism of arginine in bacteria. *Microbiological Reviews*, 50(3), 314.
- Davis, A. and Tannock, I. (2002). Tumor Physiology and Resistance to Chemotherapy: Repopulation and Drug Penetration. In B. Andersson & D. Murray (Eds.), *Clinically Relevant Resistance in Cancer Chemotherapy* (Vol. 112, pp. 1-26): Springer US.
- Di Carlo, E., Forni, G., Lollini, P., Colombo, M.P., Modesti, A. and Musiani, P. (2001). The intriguing role of polymorphonuclear neutrophils in antitumor reactions. *Blood*, 97(2), 339-345.
- Dieckmann, R., Helmuth, R., Erhard, M. and Malorny, B. (2008). Rapid classification and identification of salmonellae at the species and subspecies levels by whole-cell matrix-assisted laser desorption ionization-time of flight mass spectrometry. *Applied and Environmental Microbiology*, 74(24), 7767-7778.
- Dinarello, C.A. (1997). Proinflammatory and anti-inflammatory cytokines as mediators in the pathogenesis of septic shock. *Chest Journal*, 112(6_Supplement), 321S-329S.
- Dorman, C. (2009). Global regulators and environmental adaptation in Gram negative pathogens. *Clinical Microbiology and Infection*, 15(s1), 47-50.
- Drecktrah, D., Knodler, L.A., Galbraith, K. and Steele-Mortimer, O. (2005). The *Salmonella* SPI1 effector SopB stimulates nitric oxide production long after invasion. *Cellular Microbiology*, 7(1), 105-113.
- Eckmann, L., Rudolf, M.T., Ptasznik, A., Schultz, C., Jiang, T., Wolfson, N., Tsien, R., Fierer, J., Shears, S.B. and Kagnoff, M.F. (1997). D-myo-Inositol 1, 4, 5, 6-tetrakisphosphate produced in human intestinal epithelial cells in response to *Salmonella* invasion inhibits phosphoinositide 3-kinase signaling pathways. *Proceedings of the National Academy of Sciences*, 94(26), 14456-14460.
- Edsall, G., Gaines, S., Landy, M., Tigertt, W., Sprinz, H., Trapani, R.J., Mandel, A.D. and Benenson, A. (1960). Studies on infection and immunity in experimental typhoid fever I. Typhoid fever in chimpanzees orally infected with *Salmonella typhosa*. *The Journal of Experimental Medicine*, 112(1), 143-166.

- Emes, R.D., Goodstadt, L., Winter, E.E. and Ponting, C.P. (2003). Comparison of the genomes of human and mouse lays the foundation of genome zoology. *Human Molecular Genetic*, 12,701-9.
- Engelbart, K. and Gericke, D. (1964). Oncolysis by clostridia V. Transplanted tumors of the hamster. *Cancer Research*, 24(2 Part 1), 239-243.
- Escartín, E.F., Lozano, J.S. and Garcia, O.R. (2000). Quantitative survival of native *Salmonella* serovars during storage of frozen raw pork. *International Journal of Food Microbiology*, 54(1), 19-25.
- Fedirko, V., Tramacere, I., Bagnardi, V., Rota, M., Scotti, L., Islami, F., Negri, E., Straif, K., Romieu, I. and La Vecchia, C. (2011). Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. *Annals of Oncology*, 22(9), 1958-1972.
- Ferat, J.L. and Michel, F. (1993). Group II self-splicing introns in bacteria. *Nature*, 364(6435):358-61.
- Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D.M., Forman, D. and Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *International Journal of Cancer*, 136(5), E359-E386.
- Fields, P.I., Swanson, R.V., Haidaris, C.G. and Heffron, F. (1986). Mutants of *Salmonella typhimurium* that cannot survive within the macrophage are avirulent. *Proceedings of the National Academy of Sciences*, 83(14), 5189-5193.
- Finlay, B. (1994). Molecular and cellular mechanisms of *Salmonella* pathogenesis *Bacterial Pathogenesis of Plants and Animals* (pp. 163-185): Springer.
- Forbes, N.S., Munn, L.L., Fukumura, D., and Jain, R.K. (2003). Sparse initial entrapment of systemically injected *Salmonella typhimurium* leads to heterogeneous accumulation within tumors. *Cancer research*, 63(17), 5188-5193.
- Frazier, C.L., San Filippo, J., Lambowitz, A.M. and Mills, D.A. (2003). Genetic manipulation of *Lactococcus lactis* by using targeted group II introns: generation of stable insertions without selection. *Applied and Environmental Microbiology*, 69(2), 1121-1128.
- Galan, J. E., & Curtiss, R. (1989). Cloning and molecular characterization of genes whose products allow *Salmonella typhimurium* to penetrate tissue culture cells. *Proceedings of the National Academy of Sciences of the United States of America*, 86(16), 6383-6387.
- Galanis, E., Wong, D.M.L.F., Patrick, M.E., Binsztein, N., Cieslik, A., Chalermchaikit, T., Aidara-Kane, A., Ellis, A., Angulo, F.J. and Wegener,

- H.C. (2006). Web-based surveillance and global *Salmonella* distribution, 2000–2002. *Emerging Infectious diseases*, 12(3), 381.
- Galyov, E.E., Wood, M.W., Rosqvist, R., Mullan, P.B., Watson, P.R., Hedges, S. and Wallis, T.S. (1997). A secreted effector protein of *Salmonella* dublin is translocated into eukaryotic cells and mediates inflammation and fluid secretion in infected ileal mucosa. *Molecular microbiology*, 25(5), 903-912.
- Gao, J., Liu, X. and Rigas, B. (2005). Nitric oxide-donating aspirin induces apoptosis in human colon cancer cells through induction of oxidative stress. *Proceedings of the National Academy of Sciences of the United States of America*, 102(47), 17207-17212.
- Garmory, H.S., Brown, K.A. and Titball, R.W. (2002). *Salmonella* vaccines for use in humans: present and future perspectives. *FEMS Microbiology Reviews*, 26(4), 339-353.
- Giacchetti, S., Itzhaki, M., Gruia, G., Adam, R., Zidani, R., Kunstlinger, F., Brienza, S., Alafaci, E., Bertheault-Cvitkovic, F. and Jasmin, C. (1999). Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. *Annals of Oncology*, 10(6), 663-669.
- Giacomodonato, M.N., Uzzau, S., Bacciu, D., Caccuri, R., Sarnacki, S.H., Rubino, S. and Cerquetti, M.C. (2007). SipA, SopA, SopB, SopD and SopE2 effector proteins of *Salmonella enterica* serovar Typhimurium are synthesized at late stages of infection in mice. *Microbiology*, 153(4), 1221-1228.
- Glatz, B.A. and Anderson, K.I. (1988). Isolation and characterization of mutants of *Propionibacterium* strains. *Journal of Dairy Science*, 71(7), 1769-1776.
- Goldstein, A., Goldstein, D.B., Brown, B.J. and Chou, S.C. (1959). Amino acid starvation in an *Escherichia coli* auxotroph: I. Effects on protein and nucleic acid synthesis and on cell division. *Biochimica et Biophysica Acta*, 36(1), 163-172.
- Gordon, R. (1959). Broiler diseases. *Veterinary Record*, 71, 994-1003.
- Grimont, P.A. and Weill, F.X. (2007). Antigenic formulae of the *Salmonella* serovars. *WHO Collaborating Centre for Reference and Research on Salmonella, Institut Pasteur, Paris, France*.
- Groisman, E.A. and Ochman, H. (1997). How *Salmonella* became a pathogen. *Trends in Microbiology*, 5(9), 343-349.
- Guenet, J.L. (2005). The mouse genome. *Genome Research*, 15, 1729-40.

- Guo, H., Karberg, M., Long, M., Jones, J., Sullenger, B. and Lambowitz, A.M. (2000). Group II introns designed to insert into therapeutically relevant DNA target sites in human cells. *Science*, 289(5478), 452-457.
- Guo, H., Zimmerly, S., Perlman, P.S., and Lambowitz, A.M. (1997). Group II intron endonucleases use both RNA and protein subunits for recognition of specific sequences in double-stranded DNA. *The EMBO Journal*, 16(22), 6835-6848.
- Hanahan, D. and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. *Cell*, 144(5), 646-674.
- Haneda, T., Ishii, Y., Danbara, H. and Okada, N. (2009). Genome-wide identification of novel genomic islands that contribute to *Salmonella* virulence in mouse systemic infection. *FEMS Microbiology Letters*, 297(2), 241-249.
- Hapfelmeier, S. and Hardt, W.D. (2005). A mouse model for *S. typhimurium*-induced enterocolitis. *Trends in Microbiology*, 13(10), 497-503.
- Hayashi, K., Zhao, M., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K. and Hoffman, R.M. (2009a). Cancer metastasis directly eradicated by targeted therapy with a modified *Salmonella typhimurium*. *Journal of Cellular Biochemistry*, 106(6), 992-998.
- Hayashi, K., Zhao, M., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., Kishimoto, H., Bouvet, M. and Hoffman, R.M. (2009b). Systemic targeting of primary bone tumor and lung metastasis of high-grade osteosarcoma in nude mice with a tumor-selective strain of *Salmonella typhimurium*. *Cell Cycle*, 8(6), 870-875.
- Heald, R.J. and Ryall, R.D. (1986). Recurrence and survival after total mesorectal excision for rectal cancer. *Lancet*, 1(8496), 1479-1482.
- Hensel, M. (2000). *Salmonella* pathogenicity island 2. *Molecular Microbiology*, 36(5), 1015-1023.
- Hockel, M. and Vaupel, P. (2001a). Biological consequences of tumor hypoxia. *Seminars in Oncology*, 28(2), 36-41.
- Hockel, M. and Vaupel, P. (2001b). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *Journal of the National Cancer Institute*, 93(4), 266-276.
- Holohan, C., Van Schaeybroeck, S., Longley, D.B. and Johnston, P.G. (2013). Cancer drug resistance: an evolving paradigm. *Nature Reviews Cancer*, 13(10), 714-726.

- Hu, B., Kou, L., Li, C., Zhu, L., Fan, Y., Wu, Z., Wang, J. and Xu, G. (2009). Bifidobacterium longum as a delivery system of TRAIL and endostatin cooperates with chemotherapeutic drugs to inhibit hypoxic tumor growth. *Cancer Gene Therapy*, 16(8), 655-663.
- Huang, B., Zhao, J., Shen, S., Li, H., He, K.L., Shen, G.X., Mayer, L., Unkeless, J., Li, D. and Yuan, Y. (2007). *Listeria monocytogenes* promotes tumor growth via tumor cell toll-like receptor 2 signaling. *Cancer Research*, 67(9), 4346-4352.
- Hueck, C.J. (1998). Type III protein secretion systems in bacterial pathogens of animals and plants. *Microbiology and Molecular Biology Reviews*, 62(2), 379-433.
- Ikeda, H., Chamoto, K., Tsuji, T., Suzuki, Y., Wakita, D., Takeshima, T. and Nishimura, T. (2004). The critical role of type-1 innate and acquired immunity in tumor immunotherapy. *Cancer Science*, 95(9), 697-703.
- Jain, R.K. (1998). The next frontier of molecular medicine: delivery of therapeutics. *Nature medicine*, 4(6), 655-657.
- Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E. and Forman, D. (2011). Global cancer statistics. *CA: A Cancer Journal for Clinicians*, 61(2), 69-90.
- Jess, T., Rungoe, C. and Peyrin-Biroulet, L. (2012). Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies. *Clinical Gastroenterology and Hepatology*, 10(6), 639-645.
- Jiang, X., Rossanese, O.W., Brown, N.F., Kujat-Choy, S., Galan, J. E., Finlay, B.B. and Brumell, J. H. (2004). The related effector proteins SopD and SopD2 from *Salmonella enterica* serovar Typhimurium contribute to virulence during systemic infection of mice. *Molecular microbiology*, 54(5), 1186-1198.
- Jones, M.A., Wood, M.W., Mullan, P.B., Watson, P.R., Wallis, T.S. and Galyov, E.E. (1998). Secreted effector proteins of *Salmonella dublin* act in concert to induce enteritis. *Infection and Immunity*, 66(12), 5799-5804.
- Kadonaga, J.T. and Knowles, J.R. (1985). A simple and efficient method for chemical mutagenesis of DNA. *Nucleic Acids Research*, 13(5), 1733-1745.
- Kaimala, S., Mohamed, Y.A., Nader, N., Issac, J., Elkord, E., Chouaib, S., Fernandez-Cabezudo, M. J. and Al-Ramadi, B. K. (2014). *Salmonella*-mediated tumor regression involves targeting of tumor myeloid suppressor cells causing a shift to M1-like phenotype and reduction in suppressive capacity. *Cancer Immunology, Immunotherapy*, 63(6), 587-599.

- Karberg, M., Guo, H., Zhong, J., Coon, R., Perutka, J. and Lambowitz, A. M. (2001). Group II introns as controllable gene targeting vectors for genetic manipulation of bacteria. *Nature biotechnology*, 19(12), 1162-1167.
- Kasinskas, R.W. and Forbes, N.S. (2007). *Salmonella typhimurium* lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. *Cancer Research*, 67(7), 3201-3209.
- Khoo, C.H. (2011). Characterization and development of the genetically modified *Salmonella enterica* Subsp. *enterica* (*S. Typhimurium* and *S. Agona* Δ SopB Δ SopD Δ PipD Mutants.). *PhD Thesis*.
- Kimura, N.T., Taniguchi, S.i., Aoki, K. and Baba, T. (1980). Selective localization and growth of *Bifidobacterium bifidum* in mouse tumors following intravenous administration. *Cancer research*, 40(6), 2061-2068.
- King, I., Bermudes, D., Lin, S., Belcourt, M., Pike, J., Troy, K., Le, T., Ittensohn, M., Mao, J. and Lang, W. (2002). Tumor-targeted *Salmonella* expressing cytosine deaminase as an anticancer agent. *Human gene therapy*, 13(10), 1225-1233.
- Klemm, F. and Joyce, J. A. (2014). Microenvironmental regulation of therapeutic response in cancer. *Trends in Cell Biology*, 25(4), 198-213.
- Koch, J., Schrauder, A., Alpers, K., Werber, D., Frank, C., Prager, R., Rabsch, W., Broll, S., Feil, F. and Roggentin, P. (2005). *Salmonella agona* outbreak from contaminated aniseed, Germany. *Emerging Infectious Diseases*, 11(7), 1124-1127.
- Kuo, T.T. and Stocker, B. (1969). Suppression of proline requirement of proA and proAB deletion mutants in *Salmonella typhimurium* by mutation to arginine requirement. *Journal of Bacteriology*, 98(2), 593-598.
- Lambowitz, A.M., Mohr, G. and Zimmerly, S. (2005). Group II intron homing endonucleases: ribonucleoprotein complexes with programmable target specificity. *Nucleic Acids and Molecular Biology*, 16, 121-145
- Lambowitz, A.M. and Zimmerly, S. (2004). Mobile group II introns. *Annual Review Genetics*, 38, 1-35.
- Lawley, T.D., Chan, K., Thompson, L.J., Kim, C.C., Govoni, G.R. and Monack, D.M. (2006). Genome-wide screen for *Salmonella* genes required for long-term systemic infection of the mouse. *PLoS Pathogens*, 2(2), e11.
- Ledwidge, R. and Blanchard, J.S. (1999). The dual biosynthetic capability of N-acetylornithine aminotransferase in arginine and lysine biosynthesis. *Biochemistry*, 38(10), 3019-3024.

- Lee, C.H. (2012). Engineering bacteria toward tumor targeting for cancer treatment: current state and perspectives. *Applied Microbiology and Biotechnology*, 93(2), 517-523.
- Lee, C.H., Wu, C., Chen, S. and Shiau, A.L. (2009). Humoral immune responses inhibit the antitumor activities mediated by *Salmonella enterica* serovar Choleraesuis. *Journal of Immunotherapy*, 32(4), 376-388.
- Lee, C.H., Wu, C.L. and Shiau, A.L. (2005). Systemic administration of attenuated *Salmonella choleraesuis* carrying thrombospondin-1 gene leads to tumor-specific transgene expression, delayed tumor growth and prolonged survival in the murine melanoma model. *Cancer gene therapy*, 12(2), 175-184.
- Lee, C.H., Wu, C.L. and Shiau, A.L. (2008). Toll-like receptor 4 mediates an antitumor host response induced by *Salmonella choleraesuis*. *Clinical Cancer Research*, 14(6), 1905-1912.
- Lee, H.P., Lee, J. and Shanmugaratnam, K. (1987). Trends and ethnic variation in incidence and mortality from cancers of the colon and rectum in Singapore, 1968 to 1982. *Annals Academy of Medicine Singapore*, 16(3), 397-401.
- Lee, K.C., Zheng, L.M., Margitich, D., Almassian, B. and King, I. (2000). Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and *Escherichia coli* cytosine deaminase gene-incorporated *Salmonella* strain, TAPET-CD, being developed as an antitumor agent. *International Journal of Toxicology*, 20(4), 207-217.
- Lee, Y.H., Brown, M. and Cheung, H.Y. (1982). Defined minimal media for the growth of prototrophic and auxotrophic strains of *Bacillus stearothermophilus*. *Journal of Applied Bacteriology*, 53(2), 179-187.
- Lehouritis, P., Springer, C. and Tangney, M. (2013). Bacterial-directed enzyme prodrug therapy. *Journal of Controlled Release*, 170(1), 120-131.
- Leschner, S. and Weiss, S. (2010). *Salmonella* allies in the fight against cancer. *Journal of Molecular Medicine*, 88(8), 763-773.
- Leung, K. and Finlay, B. (1991). Intracellular replication is essential for the virulence of *Salmonella typhimurium*. *Proceedings of the National Academy of Sciences*, 88(24), 11470-11474.
- Li, B., He, H., Zhang, S., Zhao, W., Li, N. and Shao, R. (2012). *Salmonella typhimurium* strain SL7207 induces apoptosis and inhibits the growth of HepG2 hepatoma cells in vitro and in vivo. *Acta Pharmaceutica Sinica B*, 2(6), 562-568.

- Li, X., Fu, G.F., Fan, Y.R., Liu, W.H., Liu, X.J., Wang, J.J. and Xu, G.X. (2003). Bifidobacterium adolescentis as a delivery system of endostatin for cancer gene therapy: selective inhibitor of angiogenesis and hypoxic tumor growth. *Cancer Gene Therapy*, 10(2), 105-111.
- Liang, P.S., Chen, T.Y. and Giovannucci, E. (2009). Cigarette smoking and colorectal cancer incidence and mortality: systematic review and meta-analysis. *International Journal of Cancer*, 124(10), 2406-2415.
- Lin, F., Wang, X., Hsu, H., Mumaw, V. and Nakoneczna, I. (1987). Electron microscopic studies on the location of bacterial proliferation in the liver in murine salmonellosis. *British Journal of Experimental Pathology*, 68(4), 539.
- Lodish, H., Berk, A., Zipursky, S. L., Matsudaira, P., Baltimore, D. and Darnell, J. (2000). Tumor cells and the onset of cancer. *Molecular Cell Biology*, 4th edition.
- Lovitt, R., Kell, D. and Morris, J. (1987). The physiology of Clostridium sporogenes NCIB 8053 growing in defined media. *Journal of Applied Bacteriology*, 62(1), 81-92.
- Low, K.B., Ittensohn, M., Le, T., Platt, J., Sodi, S., Amoss, M., Ash, O., Carmichael, E., Chakraborty, A. and Fischer, J. (1999). Lipid A mutant *Salmonella* with suppressed virulence and TNF α induction retain tumor-targeting in vivo. *Nature Biotechnology*, 17(1), 37-41.
- Luo, X., Ittensohn, M., Low, B., Pawelek, J., Li, Z., Ma, X. and Bermudes, D. (1999). Genetically modified *Salmonella* typhimurium inhibited growth of primary tumors and metastase. *Proceeding Annual Meeting American Association Cancer Research*, 40, 3146.
- Luo, X., Li, Z., Lin, S., Le, T., Ittensohn, M., Bermudes, D., Runyab, J.D., Shen, S., Chen, J. and King, I.C. (2001). Antitumor effect of VNP20009, an attenuated *Salmonella*, in murine tumor models. *Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics*, 12(11-12), 501-508.
- Ma, Y., Yang, Y., Wang, F., Zhang, P., Shi, C., Zou, Y. and Qin, H. (2013). Obesity and risk of colorectal cancer: a systematic review of prospective studies. *PLoS One*, 8(1), e53916.
- Maciag, P.C., Radulovic, S. and Rothman, J. (2009). The first clinical use of a live-attenuated *Listeria monocytogenes* vaccine: a Phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. *Vaccine*, 27(30), 3975-3983.
- Majowicz, S.E., Musto, J., Scallan, E., Angulo, F.J., Kirk, M., O'Brien, S.J., Jones, T. F., Fazil, A. and Hoekstra, R.M. (2010). The global burden of

- nontyphoidal *Salmonella* gastroenteritis. *Clinical Infectious Diseases*, 50(6), 882-889.
- Malmgren, R. A. and Flanigan, C.C. (1955). Localization of the vegetative form of *Clostridium tetani* in mouse tumors following intravenous spore administration. *Cancer Research*, 15(7), 473-478.
- Marcus, S.L., Brumell, J.H., Pfeifer, C.G. and Finlay, B.B. (2000). *Salmonella* pathogenicity islands: big virulence in small packages. *Microbes and Infection*, 2(2), 145-156.
- Marijnen, C., Kapiteijn, E., Van de Velde, C., Martijn, H., Steup, W., Wiggers, T., Kranenbarg, E.K. and Leer, J. (2002). Acute side effects and complications after short-term preoperative radiotherapy combined with total mesorectal excision in primary rectal cancer: report of a multicenter randomized trial. *Journal of Clinical Oncology*, 20(3), 817-825.
- Martinez-Abarca, F. and Toro, N. (2000). Group II introns in the bacterial world. *Molecular Microbiology*, 38(5), 917-926.
- Mastroeni, P. and Menager, N. (2003). Development of acquired immunity to *Salmonella*. *Journal of Medical Microbiology*, 52(6), 453-459.
- McCarthy, E.F. (2006). The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. *The Iowa Orthopaedic Journal*, 26, 154.
- McCourt, J. and Duggleby, R. (2006). Acetohydroxyacid synthase and its role in the biosynthetic pathway for branched-chain amino acids. *Amino Acids*, 31(2), 173-210.
- McCusker, M.P., Hokamp, K., Buckley, J.F., Wall, P.G., Martins, M. and Fanning, S. (2014). Complete genome sequence of *Salmonella enterica* serovar Agona pulsed-field type SAGOXB. 0066, cause of a 2008 pan-European outbreak. *Genome Announcements*, 2(1), e01219-01213.
- McFarland, W.C. and Stocker, B.A. (1987). Effect of different purine auxotrophic mutations on mouse-virulence of a Vi-positive strain of *Salmonella dublin* and of two strains of *Salmonella typhimurium*. *Microbial Pathogenesis*, 3(2), 129-141.
- Meads, M.B., Gatenby, R.A. and Dalton, W.S. (2009). Environment-mediated drug resistance: a major contributor to minimal residual disease. *Nature Reviews Cancer*, 9(9), 665-674.
- Medina, C., Camacho, E.M., Flores, A., Mesa-Pereira, B. and Santero, E. (2011). Improved expression systems for regulated expression in *Salmonella* infecting eukaryotic cells. *PloS One*, 6(8), e23055.

- Mengesha, A., Wei, J.Z., Zhou, S.F. and Wei, M.Q. (2010). Clostridial spores to treat solid tumours-potential for a new therapeutic modality. *Current Gene Therapy*, 10(1), 15-26.
- Mirolid, S., Ehrbar, K., Weissmüller, A., Prager, R., Tschape, H., Russmann, H. and Hardt, W.D. (2001). *Salmonella* Host Cell Invasion Emerged by Acquisition of a Mosaic of Separate Genetic Elements, Including *Salmonella* Pathogenicity Island 1 (SPI1), SPI5, and sopE2. *Journal of Bacteriology*, 183(7), 2348-2358.
- Mittrucker, H.W. and Kaufmann, S. (2000). Immune response to infection with *Salmonella* Typhimurium in mice. *Journal of Leukocyte Biology*, 67(4), 457-463.
- Modarressi, S. and Thong, K.L. (2010). Isolation and molecular sub typing of *Salmonella* Enterica from chicken, beef and street foods in Malaysia. *Scientific Research and Essays*, 5(18), 2713-2720.
- Mohr, G., Smith, D., Belfort, M. and Lambowitz, A.M. (2000). Rules for DNA target-site recognition by a lactococcal group II intron enable retargeting of the intron to specific DNA sequences. *Genes and Development*, 14(5), 559-573.
- Moran, A.B. (1961). Occurrence and distribution of *Salmonella* in animals in the United States. *Proceeding 65th Annual Meeting US Livestock San Francisco Association*, 441-448.
- Morrissey, D., O'Sullivan, G.C. and Tangney, M. (2010). Tumour targeting with systemically administered bacteria. *Current Gene Therapy*, 10(1), 3-14.
- Mottram, J. (1936). A factor of importance in the radio sensitivity of tumours. *The British Journal of Radiology*, 9(105), 606-614.
- Mou, X., Wan, S., Li, Y., Zhang, S., Sun, M., Liu, F., Fu, H., Zhang, X., Liu, H. and Cao, Q. (2011). Phenotypic pattern-based assay for dynamically monitoring host cellular responses to *Salmonella* infections. *PloS One*, 6.
- Nagakura, C., Hayashi, K., Zhao, M., Yamauchi, K., Yamamoto, N., Tsuchiya, H., Tomita, K., Bouvet, M. and Hoffman, R.M. (2009). Efficacy of a genetically-modified *Salmonella* Typhimurium in an orthotopic human pancreatic cancer in nude mice. *Anticancer Research*, 29(6), 1873-1878.
- Nemunaitis, J., Cunningham, C., Senzer, N., Kuhn, J., Cramm, J., Litz, C., Cavagnolo, R., Cahill, A., Clairmont, C. and Sznol, M. (2003). Pilot trial of genetically modified, attenuated *Salmonella* expressing the *E. coli* cytosine deaminase gene in refractory cancer patients. *Cancer Gene Therapy*, 10(10), 737-744.

- Ochman, H., Soncini, F.C., Solomon, F. and Groisman, E.A. (1996). Identification of a pathogenicity island required for *Salmonella* survival in host cells. *Proceedings of the National Academy of Sciences of the United States of America*, 93(15), 7800-7804.
- Paget, S. (1889). The distribution of secondary growths in cancer of the breast. *The Lancet*, 133(3421), 571-573.
- Pardon, P., Sanchis, R., Marly, J., Lantier, F., Pepin, M. and Popoff, M. (1987). Ovine salmonellosis caused by *Salmonella abortus ovis*. *Annals of Veterinary Research*, 19(4), 221-235.
- Park, J.M., Jang, Y.S., Kim, T.Y. and Lee, S.Y. (2010). Development of a gene knockout system for *Ralstonia eutropha* H16 based on the broad-host-range vector expressing a mobile group II intron. *FEMS Microbiology Letters*, 309(2), 193-200.
- Parker, R.C., Plummer, H.C., Siebenmann, C.O. and Chapman, M.G. (1947). Effect of histolytic infection and toxin on transplantable mouse tumors. *Experimental Biology and Medicine*, 66(2), 461-467.
- Patel, J.C. and Galan, J.E. (2005). Manipulation of the host actin cytoskeleton by *Salmonella*-all in the name of entry. *Current Opinion in Microbiology*, 8(1), 10-15.
- Paterson, Y., Guirnalda, P.D. and Wood, L.M. (2010). *Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Seminar Immunology*, 22(3), 183-9.
- Pawelek, J.M., Low, K.B. and Bermudes, D. (1997). Tumor-targeted *Salmonella* as a novel anticancer vector. *Cancer Research*, 57(20), 4537-4544.
- Pawelek, J.M., Low, K.B. and Bermudes, D. (2003). Bacteria as tumour-targeting vectors. *The Lancet Oncology*, 4(9), 548-556.
- Pecorino, L. (2012). Molecular biology of cancer: mechanisms, targets, and therapeutics: *Oxford university press*.
- Perutka, J., Wang, W., Goerlitz, D. and Lambowitz, A.M. (2004). Use of computer-designed group II introns to disrupt *Escherichia coli* DExH/D-box protein and DNA helicase genes. *Journal of Molecular Biology*, 336(2), 421-439.
- Pourhoseingholi, M.A. (2012). Increased burden of colorectal cancer in Asia. *World Journal of Gastrointestinal Oncology*, 4(4), 68-70.
- Pui, C.F., Wong, W.C., Chai, L.C., Nillian, E., Ghazali, F.M., Cheah, Y.K., Nakaguchi, Y., Nishibuchi, M. and Radu, S. (2011). Simultaneous detection of *Salmonella* spp., *Salmonella* Typhi and *Salmonella*

- Typhimurium in sliced fruits using multiplex PCR. *Food Control*, 22(2), 337-342.
- Raffatellu, M., Chessa, D., Wilson, R.P., Tükel, Ç., Akcelik, M. and Baumler, A.J. (2006). Capsule-mediated immune evasion: a new hypothesis explaining aspects of typhoid fever pathogenesis. *Infection and Immunity*, 74(1), 19-27.
- Raffatellu, M., Wilson, R.P., Chessa, D., Andrews-Polymenis, H., Tran, Q.T., Lawhon, S., Khare, S., Adams, L.G. and Baumler, A.J. (2005). SipA, SopA, SopB, SopD, and SopE2 contribute to *Salmonella enterica* serotype Typhimurium invasion of epithelial cells. *Infection and Immunity*, 73(1), 146-154.
- Rajasekaran, P., Seleem, M.N., Contreras, A., Purwantini, E., Schurig, G.G., Sriranganathan, N. and Boyle, S.M. (2008). *Brucella abortus* strain RB51 leucine auxotroph as an environmentally safe vaccine for plasmid maintenance and antigen overexpression. *Applied and Environmental Microbiology*, 74(22), 7051-7055.
- Ramos, L.S., Lehman, B.L., Peter, K.A. and McNellis, T.W. (2014). Mutation of the *Erwinia amylovora* *argD* Gene Causes Arginine Auxotrophy, Nonpathogenicity in Apples, and Reduced Virulence in Pears. *Applied and Environmental Microbiology*, 80(21), 6739-6749.
- Raupach, B. and Kaufmann, S.H. (2001). Bacterial virulence, proinflammatory cytokines and host immunity: how to choose the appropriate *Salmonella* vaccine strain? *Microbes and Infection*, 3(14), 1261-1269.
- Riley, M. and Glansdorff, N. (1983). Cloning the *Escherichia coli* K-12 *argD* gene specifying acetylornithine δ -transaminase. *Gene*, 24(2), 335-339.
- Rodriguez, S.A., Yu, J.J., Davis, G., Arulanandam, B.P. and Klose, K.E. (2008). Targeted inactivation of *Francisella tularensis* genes by group II introns. *Applied and Environmental Microbiology*, 74(9), 2619-2626.
- Rosu, V., Chadfield, M.S., Santona, A., Christensen, J.P., Thomsen, L.E., Rubino, S. and Olsen, J.E. (2007). Effects of *crp* deletion in *Salmonella enterica* serotype Gallinarum. *Acta Veterinaria Scandinavica*, 49(1), 14.
- Rothman, J., Wallecha, A., Maciag, P.C., Rivera, S., Shahabi, V. and Paterson, Y. (2010). The use of living *Listeria monocytogenes* as an active immunotherapy for the treatment of cancer. *Emerging Cancer Therapy*, 2, 13-48.
- Saccheri, F., Pozzi, C., Avogadri, F., Barozzi, S., Faretta, M., Fusi, P. and Rescigno, M. (2010). Bacteria-induced gap junctions in tumors favor antigen cross-presentation and antitumor immunity. *Science Translational Medicine*, 2(44), 44ra57-44ra57.

- Salleh, N.A., Rusul, G., Hassan, Z., Reezal, A., Isa, S.H., Nishibuchi, M. and Radu, S. (2003). Incidence of *Salmonella* spp. in raw vegetables in Selangor, Malaysia. *Food Control*, 14(7), 475-479.
- Sambrook, J. and Russell, D.W. (2001). Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory Press. Cold Spring Harbor, New York.
- Sampson, S.L., Dascher, C.C., Sambandamurthy, V.K., Russell, R.G., Jacobs, W.R., Bloom, B. R. and Hondalus, M.K. (2004). Protection elicited by a double leucine and pantothenate auxotroph of *Mycobacterium tuberculosis* in guinea pigs. *Infection and Immunity*, 72(5), 3031-3037.
- Sanchez-Vargas, F.M., Abu-El-Haija, M.A., and Gomez-Duarte, O.G. (2011). *Salmonella* infections: an update on epidemiology, management, and prevention. *Travel Medicine and Infectious Disease*, 9(6), 263-277.
- Santos, R.L., Zhang, S., Tsolis, R.M., Kingsley, R.A., Adams, L.G. and Baumler, A.J. (2001). Animal models of *Salmonella* infections: enteritis versus typhoid fever. *Microbes and Infection*, 3(14), 1335-1344.
- Saroj, S.D., Shashidhar, R., Karani, M. and Bandekar, J.R. (2008). Distribution of *Salmonella* pathogenicity island (SPI)-8 and SPI-10 among different serotypes of *Salmonella*. *Journal of Medical Microbiology*, 57(4), 424-427.
- Selwood, K. (2009). Side effects of chemotherapy. *Cancer in Children and Young People: Acute Nursing Care*, 35-71.
- Singh, N.N. and Lambowitz, A.M. (2001). Interaction of a group II intron ribonucleoprotein endonuclease with its DNA target site investigated by DNA footprinting and modification interference. *Journal of Molecular Biology*, 309(2), 361-386.
- Smith, H.W and Jones, J. (1967). Observations on experimental oral infection with *Salmonella* dublin in calves and *Salmonella* choleraesuis in pigs. *The Journal of Pathology and Bacteriology*, 93(1), 141-156.
- Smith, T. (1894). The hog-cholera group of bacteria. *US Bur Anim Ind Bull*, 6, 6-40.
- Solari, C., Mandarino, J., Panizzutti, M. and Farias, R. (2003). A new serovar and a new serological variant belonging to *Salmonella enterica* subspecies diarizonae. *Memórias do Instituto Oswaldo Cruz*, 98(4), 501-502.
- Solly, K., Wang, X., Xu, X., Strulovici, B. and Zheng, W. (2004). Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. *Assay and Drug Development Technologies*, 2(4), 363-372.

- Sorensen, O., Van Donkersgoed, J., McFall, M., Manninen, K., Gensler, G. and Ollis, G. (2002). *Salmonella* spp. shedding by Alberta beef cattle and the detection of *Salmonella* spp. in ground beef. *Journal of Food Protection*, 65(3), 484-491.
- Soyer, Y., Orsi, R.H., Rodriguez-Rivera, L.D., Sun, Q. and Wiedmann, M. (2009). Genome wide evolutionary analyses reveal serotype specific patterns of positive selection in selected *Salmonella* serotypes. *BMC Evolutionary Biology*, 9(1), 264.
- Srikanth, C., Wall, D.M., Maldonado-Contreras, A., Shi, H.N., Zhou, D., Demma, Z., Mummy, K. L. and McCormick, B.A. (2010). *Salmonella* pathogenesis and processing of secreted effectors by caspase-3. *Science*, 330(6002), 390-393.
- St Jean, A.T., Zhang, M. and Forbes, N.S. (2008). Bacterial therapies: completing the cancer treatment toolbox. *Current Opinion Biotechnology*, 19(5), 511-517.
- Sung, J.J., Lau, J. Y., Goh, K. L. and Leung, W.K. (2005). Increasing incidence of colorectal cancer in Asia: implications for screening. *The Lancet Oncology*, 6(11), 871-876.
- Tangney, M., Van Pijkeren, J.P. and Gahan, C.G. (2010). The use of *Listeria monocytogenes* as a DNA delivery vector for cancer gene therapy. *Bioengineered Bugs*, 1(4), 286-289.
- Taniguchi, S.i., Fujimori, M., Sasaki, T., Tsutsui, H., Shimatani, Y., Seki, K. and Amano, J. (2010). Targeting solid tumors with non-pathogenic obligate anaerobic bacteria. *Cancer Science*, 101(9), 1925-1932.
- Tannock, I.F., Lee, C.M., Tunggal, J.K., Cowan, D.S. and Egorin, M.J. (2002). Limited penetration of anticancer drugs through tumor tissue a potential cause of resistance of solid tumors to chemotherapy. *Clinical Cancer Research*, 8(3), 878-884.
- Taylor, D.P., Burt, R.W., Williams, M.S., Haug, P.J. and Cannon-Albright, L.A. (2010). Population-based family history-specific risks for colorectal cancer: a constellation approach. *Gastroenterology*, 138(3), 877-885.
- Teicher, B.A., Holden, S.A., Al-Achi, A. and Herman, T.S. (1990). Classification of antineoplastic treatments by their differential toxicity toward putative oxygenated and hypoxic tumor subpopulations in vivo in the FSAIIC murine fibrosarcoma. *Cancer Research*, 50(11), 3339-3344.
- Thomlinson, R. and Gray, L. (1955). The histological structure of some human lung cancers and the possible implications for radiotherapy. *British Journal of Cancer*, 9(4), 539.

- Toley, B.J. and Forbes, N.S. (2012). Motility is critical for effective distribution and accumulation of bacteria in tumor tissue. *Integrative Biology*, 4(2), 165-176.
- Toro, N., Jimenez-Zurdo, J.I. and García-Rodríguez, F.M. (2007). Bacterial group II introns: not just splicing. *FEMS Microbiology Reviews*, 31(3), 342-358.
- Toso, J.F., Gill, V.J., Hwu, P., Marincola, F.M., Restifo, N.P., Schwartzentruber, D.J., Sherry, R.M., Topalian, S.L., Yang, J.C. and Stock, F. (2002). Phase I study of the intravenous administration of attenuated *Salmonella* typhimurium to patients with metastatic melanoma. *Journal of Clinical Oncology*, 20(1), 142-152.
- Tredan, O., Galmarini, C.M., Patel, K. and Tannock, I. F. (2007). Drug resistance and the solid tumor microenvironment. *Journal of the National Cancer Institute*, 99(19), 1441-1454.
- Upadhyay, A. and Srivastava, S. (2011). Phenazine-1-carboxylic acid is a more important contributor to biocontrol *Fusarium oxysporum* than pyrrolnitrin in *Pseudomonas fluorescens* strain Psd. *Microbiological Research*, 166(4), 323-335.
- Vaupel, P. (2004). The role of hypoxia-induced factors in tumor progression. *The Oncologist*, 9(Supplement 5), 10-17.
- Vaupel, P., Kelleher, D.K. and Hockel, M. (2001). Oxygenation status of malignant tumors: pathogenesis of hypoxia and significance for tumor therapy. *Seminars in oncology*, 28, 29-35.
- Vendrell, A., Gravisaco, M.J., Pasetti, M.F., Croci, M., Colombo, L., Rodríguez, C., Mongini, C. and Waldner, C.I. (2011). A novel *Salmonella* Typhi-based immunotherapy promotes tumor killing via an antitumor Th1-type cellular immune response and neutrophil activation in a mouse model of breast cancer. *Vaccine*, 29(4), 728-736.
- Wallis, T.S. and Galyov, E.E. (2000). Molecular basis of *Salmonella*-induced enteritis. *Molecular Microbiology*, 36(5), 997-1005.
- Wang, H., Seow, A. and Lee, H.P. (2004). Trends in cancer incidence among Singapore Malays: a low-risk population. *Annals Academy Medicine Singapore*, 33(1), 57-62.
- Wang, L., Pan, L., Shi, L., Sun, Y., Zhang, Y. and Zhou, D. (1999). Roles of bifidobacterium on prevention of experimental colorectal carcinoma and induction of apoptosis. *Zhonghua yu fang yi xue za zhi [Chinese Journal of Preventive Medicine]*, 33(6), 337-339.

- Wang, X.M., Lin, F., Hsu, H., Mumaw, V. and Nakoneczna, I. (1988). Electronmicroscopic studies on the location of *Salmonella* proliferation in the murine spleen. *Journal of Medical Microbiology*, 25(1), 41-47.
- Wei, M.Q., Ellem, K. A., Dunn, P., West, M.J., Bai, C.X. and Vogelstein, B. (2007). Facultative or obligate anaerobic bacteria have the potential for multimodality therapy of solid tumours. *European Journal of Cancer*, 43(3), 490-496.
- Wei, M.Q., Mengesha, A., Good, D. and Anne, J. (2008). Bacterial targeted tumour therapy-dawn of a new era. *Cancer letters*, 259(1), 16-27.
- Welsh, R., Jensen, F., Cooper, N., Oldstone, M., Banapour, B., Sernatiriger, J., Levy, J., Hoshino, H., Tanaka, H. and Miwa, M. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. *Nature*, 379, 4.
- Wilson, T., Longley, D. and Johnston, P. (2006). Chemoresistance in solid tumours. *Annals of oncology*, 17(10), 315-324.
- Wisner, A., White, A., Potter, A., Desin, T. and Koster, W. (2012). *The Salmonella Pathogenicity Island-1 and-2 Encoded Type III Secretion Systems*: INTECH Open Access Publisher.
- Wood, M.W., Jones, M.A., Watson, P.R., Hedges, S., Wallis, T.S. and Galyov, E.E. (1998). Identification of a pathogenicity island required for *Salmonella* enteropathogenicity. *Molecular Microbiology*, 29(3), 883-891.
- Wray, C. and Sojka, W.J. (1977). Reviews of the progress of dairy science: bovine salmonellosis. *Journal of Dairy Research*, 44(2), 383-425.
- Wright, B.E. and Minnick, M.F. (1997). Reversion rates in a *LeuB* auxotroph of *Escherichia coli* K-12 correlate with ppGpp levels during exponential growth. *Microbiology*, 143(3), 847-854.
- Xu, H., Hsu, H., Moncure, C. and King, R. (1993). Correlation of antibody titres induced by vaccination with protection in mouse typhoid. *Vaccine*, 11(7), 725-729.
- Yam, C., Zhao, M., Hayashi, K., Ma, H., Kishimoto, H., McElroy, M., Bouvet, M. and Hoffman, R.M. (2010). Monotherapy with a tumor-targeting mutant of *S. typhimurium* inhibits liver metastasis in a mouse model of pancreatic cancer. *Journal of Surgical Research*, 164(2), 248-255.
- Yao, J., Zhong, J., Fang, Y., Geisinger, E., Novick, R.P. and Lambowitz, A.M. (2006). Use of targetrons to disrupt essential and nonessential genes in *Staphylococcus aureus* reveals temperature sensitivity of L1. LtrB group II intron splicing. *Rna*, 12(7), 1271-1281.

- Yazawa, K., Fujimori, M., Nakamura, T., Sasaki, T., Amano, J., Kano, Y. and Taniguchi, S.I. (2001). Bifidobacterium longum as a delivery system for gene therapy of chemically induced rat mammary tumors. *Breast Cancer Research and Treatment*, 66(2), 165-170.
- Yoon, W.S., Chae, Y.S., Hong, J. and Park, Y.K. (2011). Antitumor therapeutic effects of a genetically engineered *Salmonella* typhimurium harboring TNF- α in mice. *Applied Microbiology and Biotechnology*, 89(6), 1807-1819.
- Yu, B., Yang, M., Shi, L., Yao, Y., Jiang, Q., Li, X., Tang, L.H., Zheng, B.J., Yuen, K.Y. and Smith, D.K. (2012). Explicit hypoxia targeting with tumor suppression by creating an "obligate" anaerobic *Salmonella* Typhimurium strain. *Scientific Reports*, 2, 436.
- Zainal Ariffin, O. and Nor Saleha, I. (2011). National cancer registry report: Malaysia cancer statistics-data and figure 2007. *Putrajaya, Ministry of Health Malaysia*.
- Zhang, S., Santos, R.L., Tsolis, R.M., Stender, S., Hardt, W.D., Baumler, A.J. and Adams, L.G. (2002). The *Salmonella enterica* serotype typhimurium effector proteins SipA, SopA, SopB, SopD, and SopE2 act in concert to induce diarrhea in calves. *Infection and Immunity*, 70(7), 3843-3855.
- Zhang, Y., Tome, Y., Suetsugu, A., Zhang, L., Zhang, N., Hoffman, R.M. and Zhao, M. (2012). Determination of the optimal route of administration of *Salmonella* typhimurium A1-R to target breast cancer in nude mice. *Anticancer Research*, 32(7), 2501-2508.
- Zhao, M., Geller, J., Ma, H., Yang, M., Penman, S. and Hoffman, R.M. (2007). Monotherapy with a tumor-targeting mutant of *Salmonella* typhimurium cures orthotopic metastatic mouse models of human prostate cancer. *Proceedings of the National Academy of Sciences*, 104(24), 10170-10174.
- Zhao, M., Yang, M., Li, X.M., Jiang, P., Baranov, E., Li, S., Xu, M., Penman, S. and Hoffman, R.M. (2005). Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing *Salmonella* typhimurium. *Proceedings of the National Academy of Sciences of the United States of America*, 102(3), 755-760.
- Zhao, M., Yang, M., Ma, H., Li, X., Tan, X., Li, S., Yang, Z. and Hoffman, R. M. (2006). Targeted therapy with a *Salmonella* typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. *Cancer Research*, 66(15), 7647-7652.
- Zhong, J., Karberg, M. and Lambowitz, A.M. (2003). Targeted and random bacterial gene disruption using a group II intron (targetron) vector containing a retrotransposition-activated selectable marker. *Nucleic Acids Research*, 31(6), 1656-1664.